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ABSTRACT
Background: Neurohormonal activation and abnormalities in growth hormone and testosterone concentrations have been 
reported in heart failure (HF). Erectile dysfunction(ED) is common in these patients and contributes to a low quality of 
life. No data are known regarding the correlation between testosterone and hemodynamics, exercise capacity and cardiac 
function in HF patients with ED, a marker of endothelial dysfunction. The aim of this study was to correlate testosterone 
levels with cardiac function, hemodynamic and exercise capacity in HF patients with ED.
Materials and Methods: Fifteen HF patients underwent a six-minute treadmill cardiopulmonary walking test (6’CWT) 
and, ten minutes later, a maximum cardiopulmonary exercise test. Also, testosterone and other hormones were determined 
at rest.
Results: Among hemodynamic variables only diastolic blood pressure on 6’CWT was correlated with testosterone levels(r 
=- 0.66, p = 0.007). The variables on exercise tests, VE/VCO2 slope and oxygen consumption did not show any correlation, 
except the distance at 6’CWT (r = 0.50, p = 0,047). Right and left ventricle ejection fraction showed inverse correlation 
with testosterone (r =- 0.55, p = 0.03 and r =- 0.69, p = 0.004 respectively).
Conclusion: Testosterone levels correlated directly with distance at six-minute cardiopulmonary walk test and inversely 
with diastolic blood pressure, right and left ventricle ejection fraction in heart failure patients with erectile dysfunction. 
Further elucidation of mechanisms as regards testosterone action in these patients is warranted.
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INTRODUCTION
Heart failure (HF) can be considered as the 
ODVW VWDJH RI KHDUW GLVHDVH DQG D VLJQL¿FDQW FDXVH
of mortality and morbidity worldwide (1). The left 
ventricular systolic dysfunction and limited exercise 
capacity manifested by breathlessness and fatigue are 
determinants of mortality and clinical events in the 
follow-up of HF patients. (2,3). Multiple mechanisms 
have been reported to be related to exercise capac-
ity including diastolic and systolic cardiac function, 
UHÀH[PHWDEROLF YDVFXODU DQGPXVFXODU UHVSRQVH
(3). Sexual satisfaction is an important component 
WKDWLQÀXHQFHVTXDOLW\RIOLIHLQ+)SDWLHQWV(UHFWLOH
dysfunction (ED) affects 60 to 70% of HF clinic 
outpatients (4). Symptoms, hormonal abnormalities, 
hemodynamic status, medication side effects and 
psychological factors are the major contributors to 
this sexual disorder.
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In the physiopathology of chronic HF, the 
neurohormonal hypothesis for progression of heart 
failure has been considered of greater interest than the 
original hemodynamic mechanisms (5). Activation of 
sympathetic nervous system, renin-angiotensin-aldo-
sterone system, arginine vasopressin, and endothelins 
are considered as neurohormonal targets in the treat-
ment of HF. However, other hormonal abnormalities 
KDYHEHHQUHSRUWHGLQ+)VXFKDVVLJQL¿FDQWGHFUHDVH
in growth hormones, insulin-like growth factor I and 
testosterone concentrations (6). The hormonal and 
cytokine activation contributes to peripheral muscle 
tissue wasting as well as anabolic/catabolic imbal-
ance (7). In men, testosterone seems to play a role 
LQGHWHUPLQLQJDQDEROLFIXQFWLRQDQWLLQÀDPPDWRU\
and vasodilator processes. No data has been reported 
as regards testosterone’s effect on hemodynamics, 
cardiac function and exercise capacity in HF patients 
with ED.
The aim of this study was to evaluate the cor-
relation between serum testosterone levels and cardiac 
function, hemodynamics, and exercise capacity in HF 
patients with ED. In addition, we determined a HF 
KRUPRQHSUR¿OH VHUXP OHYHOV RI SURODFWLQ OXWHLQ-
izing hormone, follicle-stimulating hormone, resting 
norepinephrine, and thyroid hormones.
MATERIALS AND METHODS
Studied Population
Fifteen randomized chronic male HF pa-
tients, 50 ± 10 years with ED (Table-1) for at least 
four months, in a steady relationship and presenting 
LQWHUHVWLQVH[ZHUHLQFOXGHG('ZDVGH¿QHGDVWKH
inability to achieve or maintain a durable erection to 
permit satisfactory sexual intercourse (the 5th-item of 
the International Index of Erectile Dysfunction) (8,9). 
Patients were in stable clinical condition for three 
months without testosterone replacement or drugs 
WKDWFRXOGKDYHDIIHFWHGWHVWRVWHURQHOHYHOVDV¿QDV-
teride, opiates, glucocorticoids and anticonvulsants. 
All patients were sedentary and did not have heavy 
alcohol consumption, nephrotic syndrome or liver 
cirrhosis history. All patients were evaluated for ED 
HWLRORJ\VXFKDVDUWHULDOLQVXI¿FLHQF\YHQRXVOHDNDJH
RUSHQLOH¿EURVLV1RHWLRORJ\ZDVIRXQGH[FHSW+)
syndrome. The protocol was approved by the Ethical 
Committee of the Heart Institute. Subjects provided 
written informed consent before participation. Exclu-
VLRQFULWHULD('VHFRQGDU\WRFDXVHVRWKHUWKDQ+)
previous ED therapy, recent useof phosphodiesterase 
inhibitors, psychiatric or psychological disorders, 
unstable angina or recent myocardial infarction, syn-
cope, high-risk arrhythmias, disease with limitation 
for exercise except HF, and symptomatic hypotension 
or systolic blood pressure (SBP) < 85 mm Hg.
Exercise Protocol
We measured systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) with the patient 
in an upright position immediately before each 
exercise test, at the last minute of the six-minute 
walking test (6’WT), at maximum exercise peak, 
and at 1-minute recovery (10). Electrocardiography 
was continuously monitored. Pulmonary ventilation 
and gas exchange data were determined on a breath-
by-breath basis with a computerized system (model 
Vmax 229 Sensormedics). The six-minute walking 
test (6’WT) was performed using a programmable 
treadmill without inclination and with patient-con-
trolled speed (Series 2000, Marquette Electronics) 
at least 2 hours after a light meal and with controlled 
room temperature (21°C to 23°C). The patients were 
oriented to walk according to Borg’s scale, with 
exertion level ranging from light to somewhat hard, 
from 11 to 13. After return of heart rate (HR), SBP, 
DBP, and symptoms to basal condition, patients 
underwent a progressive exercise test using a modi-
¿HG1DXJKWRQSURWRFRO7KH\ZHUHHQFRXUDJHG WR
perform maximum exercise until exhaustion or the 
onset of non tolerated symptoms occurred and the 
respiratory exchange ratio exceeded 1.0. The peak 
oxygen consumption (peak VO2) was considered the 
maximum reached VO2 value.
Cardiac Function and Hormonal 
Determinations
The right ventricular and left ventricular 
ejection fraction (RVEF and LVEF, respectively), as 
a percentage, were determined by echocardiogram. 
Hormonal dosage at rest before the exercise test 
included determination of serum total testosterone 
ÀXRURLPPXQRDVVD\PHWKRGSURODFWLQOXWHLQL]LQJ
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hormone, norepinephrine and follicle stimulating hor-
mone. The normal value of testosterone in this study 
ZDV  QJG//LSLG SUR¿OH DVVHVVPHQWZDV
total cholesterol, HDL cholesterol, LDL cholesterol, 
Triglycerides. Due to hormonal circadian rhythms, all 
these tests were performed in the same period (early 
morning).
Statistical Analysis
The descriptive analysis was presented as 
mean and standard deviation. The variables studied 
underwent the non-parametric Spearman test for 
correlation, considering p < 0.05 (SPSS Statistical 
Software for Windows version 11.5. Inc., Chicago, 
IL, USA).
RESULTS
All patients had total testosterone serum levels 
in the range for normal subjects (200-950 ng/dL). Four 
patients had prolactin serum levels below the normal 
range (2.5-11.5 ng/mL). One patient had hypothyroid-
ism and the other hyperthyroidism. The cardiac func-
tion, left ventricular diameters, and hormonal values 
of patients are reported in Table-2. Table-3 shows the 
hemodynamic and exercise variables.
Table 1 – Characteristics of patients with erectile dysfunction.
Characteristics of Heart Failure Patients N of Patients (%) or Value
Etiology
Ischemic 22
Chagasic 22
Idiopathic dilated cardiomyopathy 26
Hypertensive 26
Valvular   4
NYHA functional class
II 83
III 13
IV   4
Diuretics 91
ACE inhibitor 67
Angiotensin II AT1 receptor antagonists   8
ß-Adrenergic receptor blocker 61
Spironolactone 61
Amiodarone 17
Isosorbide 5-mononitrate (40 mg)   9
Total cholesterol, mg/dL 203 ± 49
HDL cholesterol, mg/dL   46 ± 13
LDL cholesterol, mg/dL 130 ± 41 
Triglycerides, mg/dL   155 ± 145
Duration of ED symptoms, months   24 ± 19
Duration of CHF symptoms, months   61 ± 49
Values are mean ± SD or n (%); ACE = angiotensin-converting enzyme inhibitor, CHF-symptoms = congestive heart failure; ED = 
erectile dysfunction.
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Correlation between Testosterone Serum 
Levels and Cardiac Diameters, Cardiac 
Function, and Hemodynamic Data
Left ventricle ejection fraction (r =- 0.69, p = 
0.004) (Figure-1) and right ventricle ejection fraction 
(r =- 0.55, p = 0.03) (Figure-1) showed inverse cor-
relation with testosterone levels. SBP, DBP and heart 
rate during MCT (maximum cardiopulmonary test) 
did not show any correlation with testosterone levels 
or any hormonal serum levels except for DBP during 
the 6´WT that correlated with testosterone (r =-0.66, 
p = 0.007) (Figure-2). Left ventricular end diastolic 
diameter and left ventricular end systolic diameter 
did not show any correlation with testosterone levels 
either (Table-4)
Correlation between Hormonal Levels and 
Exercise Capacity Data
Exercise capacity variables on 6´CWT, 
VE/VCO2 slope at six minutes, oxygen consump-
tion at six minutes did not any show correlation with 
testosterone levels or hormonal serum levels. Only 
maximum distance at 6´CWT showed correlation (r 
= 0.50, p = 0.047) with testosterone levels. Also dur-
ing the MCT, maximum VE/VCO2 slope, maximum 
oxygen consumption and time of maximum test did 
not show correlation either (Table-4)
Variables of Heart Failure Patients Number of Patients or Value
LV ejection fraction (echo) % 23 ± 7
RV ejection Fraction (echo) % 28 ± 8
LV end-diastolic diameter (echo), mm   72 ± 16
LV end systolic diameter (echo), mm   58 ± 55
Hypothyroidism/hyperthyroidism   2 patients
Serum total testosterone, ng/dL (normal 200-950)   604 ± 203
Prolactin, ng/mL (normal 2.5-11.5)   4.2 ± 2.3
Luteinizing hormone, IU/L (normal 1.4-9.2)   3.6 ± 1.9
Follicle-stimulating hormone, IU/L (normal 1-12)   4.2 ± 2.8
Resting norepinephrine, pg/mL (normal 40-268)   448 ± 214
Values are mean ± SD or n (%); LV= left ventricular; RV= right ventricular.
Table 2 – Cardiac function, left ventricular diameters and hormonal values in patients with erectile dysfunction.
Table 3 – Hemodynamic and exercise variables.
Variable     p Value
HR 6m  111 ± 105 bpm
SBP 6m  141 ± 133 mmHg
DBP 6m    74 ± 71 mmHg
HR max  134 ± 127 bpm
SBP max  138 ± 128 mmHg
DBP max    78 ± 74 mmHg
Distance 6m 0.20 ± 0.03 miles
Slope 6m 31.7 ± 7
VO2 6m 11.9 ± 2.9 mL/Kg/min
Slope Max 34.3 ± 8.7
VO2 Max 17.8 ± 3.9 mL/Kg/min
Time Max 12.3 ± 8 min
HR 6m = Heart rate at last six minutes at six minutes cardiopul-
monary walking test; SBP6m = systolic blood pressure at last six 
minutes on 6m cardiopulmonary walking test; DBP6m = BP at 
last six minutes on 6m cardiopulmonary walking test; HRmax = 
Heart rate at peak on maximum cardiopulmonary test; SBP max 
= SBP at peak on maximum cardiopulmonary test; DBP max = 
DBP at peak on maximum cardiopulmonary test. Distance 6m = 
distance on 6m cardiopulmonary walking test; Slope 6min = slope 
VE/VCO2 on 6m cardiopulmonary walking test; VO26min = Oxy-
gen consumption at six minutes of 6m cardiopulmonary walking 
test; SlopeMax = Slope VE/VCO2 at maximum cardiopulmonary 
test; VO2Max = VO2 peak at maximum cardiopulmonary test; Time 
Max = Total time at maximum cardiopulmonary test.
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Figure 1 – A) Regression linear plots in all patients between total testosterone and right ventricular ejection fraction (%, by echog-
raphy). B) Regression linear plots in all patients between total testosterone serum levels and left ventricular ejection fraction (%, by 
echography).
Figure 2 – Regression linear plots in all patients between total testosterone serum levels systemic diastolic blood pressure at the last 
minute of the 6 minutes walking test.
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levels, except diastolic blood pressure and distance 
on 6’CWT. Other hormones abnormalities can be 
found in heart failure patients with erectile dysfunc-
tion.
Low testosterone levels were reported in se-
vere stroke and acute myocardial infarction (11). In 
HF, the testosterone serum levels may be low or in the 
normal range depending of the severity of the disease 
(11). Also, it has been reported that plasma levels of 
dehydroepiandrosterone sulfate decreased in patients 
with chronic HF in proportion to the severity evalu-
ated by marker of cardiac function (12). However, 
WRRXUNQRZOHGJHWKLVLVWKH¿UVWWLPHWKDWDQLQYHUVH
correlation was demonstrated between left and right 
systolic cardiac function and total testosterone serum 
levels in selected patients with HF and ED (6,13,14). 
It is also partially discordant that, after testosterone 
administration, serum total levels remained in the 
QRUPDOSK\VLRORJLFDOUDQJHDQGQRVLJQL¿FDQWFKDQJHV
were found in BNP, TNF-D or LVEF. Also, there was 
also a positive correlation between testosterone and 
cardiac output (15). However, it was concordant with 
worsening of left ventricular remodeling with testos-
terone administration. The mechanisms to explain 
RXU¿QGLQJVDUHQRWFOHDU(IIHFWVRIWHVWRVWHURQHLQ
the heart are controversial and alternative hypotheses 
could be proposed.
 7KH¿UVWK\SRWKHVLV LV WKDW WKH WRWDO WHVWRV-
terone serum blood levels could play a role in patho-
physiology of HF, worsening cardiac function. This 
is concordant with the concept that anabolic steroids 
were considered as having cardiac toxicity with al-
terations of cellular pathology and organ physiology 
similar to those seen with heart failure and cardiomy-
opathy (16). In addition, testosterone treatment in very 
high supra-physiological doses causes myocardial 
hypertrophy and stiffening (17). Investigators admin-
istrated physiologic doses of testosterone and found 
an increase in the left ventricular diameters, but did 
QRW¿QGDQ\FKDQJHLQWKH/9()
The second hypothesis, in contrast is that 
WHVWRVWHURQH VHUXP OHYHOV FRXOGKDYHEHQH¿FLDO HI-
fects on HF, and a resistance for testosterone could be 
proposed in selected HF patients (6). In rats, androgen 
therapy has been reported to improve coronary blood 
ÀRZDQGLQFUHDVHGERWKIUDFWLRQDOVKRUWHQLQJWKHUHE\
improving cardiac function. In addition, animal stud-
COMMENTS
Ours results demonstrated that there was an 
inverse correlation between right and left ventricular 
function and total testosterone serum levels in patients 
with ED. Other hemodynamic and exercise variables 
did not show a correlation with testosterone serum 
Table 4 – Linear regression results between total testos-
terone serum levels and cardiac function, and exercise 
variables.
Variable          r p Value
LVEF (in %) - 0.69 0.004
RVEF (in %) - 0.55 0.03
LVEDD (in mm) - 0.02 ns
LVESD (in mm) 0.04 ns
HR 6m 0.10 ns
SBP 6m 0.16 ns
DBP 6m - 0.66 0.007
HR max - 0.04 ns
SBP max 0.16 ns
DBP max - 0.14 ns
Distance 6m 0.50 0.047
Slope 6m - 0.11 ns
VO2 6m 0.24 ns
Slope Max - 0.21 ns
VO2 Max 0.02 ns
Time Max 0.00 ns
LVEF = Means left ventricular ejection fraction; RVEF = Right 
ventricular EF; LVEDD = LV end diastolic diameter; LVESD = 
LV end systolic diameter; HR 6m = Heart rate at last six minutes 
at six minutes cardiopulmonary walking test; SBP6m = systolic 
blood pressure at last six minutes on 6m cardiopulmonary walk-
ing test; DBP6m = BP at last six minutes on 6m cardiopulmo-
nary walking test; HRmax = Heart rate at peak on maximum 
cardiopulmonary test; SBP max = SBP at peak on maximum 
cardiopulmonary test; DBP max = DBP at peak on maximum 
cardiopulmonary test; Distance 6m = distance on 6m cardio-
pulmonary walking test; Slope 6min = Slope VE/VCO2 on 6m 
cardiopulmonary walking test; VO26min = Oxygen consumption 
at six minutes of 6m cardiopulmonary walking test; SlopeMax = 
Slope VE/VCO2 at maximum cardiopulmonary test; VO2Max = 
VO2 peak at maximum cardiopulmonary test; Time Max = total 
time at maximum cardiopulmonary test.
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renin-angiotensin system (10,28). Also, vascular ef-
fects could be dose-dependent manner, with opposite 
effects according to the dose.
Despite previous reported improvement in 
New York Heart Association functional class and 
exercise capacity, the potential prescription of tes-
tosterone for HF should be evaluated. This potential 
prescription should consider our results and previous 
study that showed the increment of left diameters in 
HF patients after testosterone administration (17). 
Further investigations should be performed concern-
ing elucidation of its action in the heart and to de-
termine if it is safe. Acute hemodynamics, exercise 
DQGIXQFWLRQDOEHQH¿FLDOHIIHFWVFDQQRWJXDUDQWHH
D VKRUW DQG ORQJWHUPEHQH¿W LQ FDUGLDF IXQFWLRQ
and primary endpoints for heart failure treatment 
(17,27).
Although this study is limited by the number 
of patients and did not include other markers of HF, 
nevertheless cardiac function could be considered as 
one of the main surrogate endpoints in heart failure. 
A better elucidation of testosterone mechanisms and 
action is warranted in a larger patient population.
CONCLUSION
Testosterone levels correlated directly with 
distance at six-minute cardiopulmonary walk test and 
inversely with diastolic blood pressure, right and left 
ventricle ejection fraction in heart failure patients 
with erectile dysfunction.
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EDITORIAL COMMENT
Decreased testosterone level was reported 
throughout a 4-year follow-up in elderly patients with 
erectile dysfunction (ED) in addition to the association 
ZLWKDQDGYHUVHPHWDEROLFSUR¿OH7HVWRVWHURQHGH-
¿FLHQF\LVDFRPPRQRFFXUUHQFHLQPHQZLWKFKURQLF
heart failure (CHF) and may underpin features of 
advanced disease, including reduced skeletal muscle 
mass and fatigue (2). Testosterone is known to act as 
a vasodilator in systemic, coronary and pulmonary 
vascular beds, as well as having anabolic properties 
(3). This effect could potentially lead to increased 
cardiac output and improved cardiovascular function 
WKDWPD\FRQWULEXWHWRWKHFOLQLFDOEHQH¿W7KHUHIRUH
administration of testosterone to men with chronic 
congestive heart failure may lead to hemodynamic
DOWHUDWLRQV )XUWKHUPRUH WHVWRVWHURQH GH¿FLHQF\ LV
positively correlated with cardiac output and exercise 
FDSDFLW\LQSDWLHQWVZLWK&+)ZKHUHDVDVLJQL¿FDQW
improvement in both these parameters has been ob-
served following testosterone replacement therapy. 
Testosterone therapy has also been shown to reduce 
FLUFXODWLQJOHYHOVRILQÀDPPDWRU\PDUNHUV71)Į
DQG,/ȕLQSDWLHQWVZLWKHVWDEOLVKHGFRURQDU\DUWHU\
GLVHDVHDQGWHVWRVWHURQHGH¿FLHQF\
Although the mechanisms are poorly un-
derstood, the improvement in exercise capacity was 
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shown to be positively correlated with the increase in 
serum testosterone level and was accompanied by a 
small increase in internal left ventricular length (2). 
As testosterone is a vasodilator, this could explain 
its anti-ischemic effects on cardiac function during 
exercise. However, it is currently unknown whether 
WKHYDVRGLODWRU\HIIHFWVRIWHVWRVWHURQHFDQLQÀXHQFH
the fatigability of skeletal muscle in a similar fashion. 
Therefore, adjunctive testosterone therapy might aug-
ment the positive effects of exercise rehabilitation on 
these clinical outcomes in hypogonadal males with 
stable CHF.
Currently, the main drawbacks in the design 
of clinical protocols and the inclusion of patients for 
the study of hormonal alteration lie in establishing 
WKHEHVWDVVD\IRU7PHDVXUHPHQWDQGLQGH¿QLQJD
baseline T cut off level. Although some limitations of 
the current study have been mentioned by the authors, 
the important feature of this study is that it addresses 
one timely and important issue, which is the correla-
tion between serum testosterone levels and cardiac 
function, hemodynamic, and exercise capacity in HF 
patients with ED.
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EDITORIAL COMMENT
In this study Bocchi, and his colleagues 
documented that testosterone (TT) levels correlated 
directly with distance at six-minute cardiopulmonary 
walk test and inversely with diastolic blood pressure, 
right and left ventricle ejection fraction in heart 
failure patients with erectile dysfunction (ED). 
Erectile dysfunction is considered an early sign of 
endothelial dysfunction and hence cardiovascular 
disorders while low TT levels are related to ED.
TT level is considered a marker of vascular 
reactivity and non-traditional risk factor (Bio Marker) 
for coronary artery disease and peripheral arterial 
disease. It is also related to low arrhythmia threshold 
and prolonged QT intervals.
Low TT level is a predictor of cardiovascular 
mortality, and marker of low exercise tolerance and 
poor quality of life. So if used as an adjuvant in treat-
PHQWRIKHDUWIDLOXUHLWPD\VLJQL¿FDQWO\LPSURYHWKH
functional capacity and symptoms of heart failure.
Although the number of cases in this study 
is limited, as stated by the authors, the paper is in-
teresting not only to the Urologist and Andrologists 
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but also to the cardiologist and general physicians. 
However, 61% of men included in this study were 
taking spironolactone, which is an anti-androgen 
UHQGHULQJLQWHUSUHWDWLRQRIWKHGDWDDOLWWOHELWGLI¿FXOW
Understanding the correlation between TT and cardiac 
IXQFWLRQVZLOOKDYHDJUHDWEHQH¿FLDOHIIHFWRQ('
patients with heart failure.
Further studies using cardiac speckle tech-
nique and tissue Doppler imaging can provide more 
accurate assessment of cardiac function and perhaps 
demonstrate a correlation between TT levels and 
cardiac function.
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